

Supplementary figure 1

Corresponding Author; Shigeki Yagyu

MACACA	MELRALLCWASLAAALEETLLNTKLETADLKWVTFPQVDGQWEELSGLDEEQHSVRTYEV	60
_ HUMAN	MELRVLLCWASLAAALEETLLNTKLETADLKWVTFPQVDGQWEELSGLDEEQHSVRTYEV	
MACACA	CDVQRAPGQAHWLRTGWVPRRGAVHVTATLRFTMLECLSLPRAGRSCKETFTVFYYESDA	120
_ HUMAN	CDVQRAPGQAHWLRTGWVPRRGAVHVTATLRFTMLECLSLPRAGRSCKETFTVFYYESDA	
MACACA	DTATALTPAWMENPYIKVDTVAEEHLTRKRPGAEATGKVNVKTLRLGPLSKAGFYLAQD	180
_ HUMAN	DTATALTPAWMENPYIKVDTVAEEHLTRKRPGAEATGKVNVKTLRLGPLSKAGFYLAQD	
MACACA	QGACMALLSLHLFYKKCAQLTVNLTRFPETVPRELVPPAVGSCVDDAVPAPGPSPSLYCR	240
_ HUMAN	QGACMALLSLHLFYKKCAQLTVNLTRFPETVPRELVPPAVGSCVDDAVPAPGPSPSLYCR	
MACACA	EDGQWAEQPVTGCSCAPGFEEAEGNTKCRACAQGTFKPLSGEGSCQPCPANSHSNNIGSA	300
_ HUMAN	EDGQWAEQPVTGCSCAPGFEEAEGNTKCRACAQGTFKPLSGEGSCQPCPANSHSNTIGSA	
MACACA	VCQCRIGYFRARTDPRGAPCTPPSAPRSVVSRLNGSSLHLEWSAPLESGGREDLTYALR	360
_ HUMAN	VCQCRVGYFRARTDPRGAPCTPPSAPRSVVSRLNGSSLHLEWSAPLESGGREDLTYALR	
MACACA	CRECRPGGSCAPCGGDLTFDPGPRDLIVEPWVVVRGLRPDFTYTFFEVTAALNGVSSLATGPV	420
_ HUMAN	CRECRPGGSCAPCGGDLTFDPGPRDLIVEPWVVVRGLRPDFTYTFFEVTAALNGVSSLATGPV	
MACACA	PFEPVNVTTDREVPPAVSDIRVTRSSPSSLSLAWAVPRAPSGAVLDYEVKYHEKGAEGPS	480
_ HUMAN	PFEPVNVTTDREVPPAVSDIRVTRSSPSSLSLAWAVPRAPSGAVLDYEVKYHEKGAEGPS	
MACACA	SVRFLIKTSENRAELRLGLKRGASYLVQVRARSEAGYGFGEHHQSQTQLDE NEGWRQ LAL	540
_ HUMAN	SVRFLIKTSENRAELRLGLKRGASYLVQVRARSEAGYGFGEHHQSQTQLDESEGWRQLAL	
MACACA	IAGTAVVGVLVLLVIVVAVLCLRQNSNGREAEYSDKHGQYLIGHGTKVYIDPFTYEDPN	600
_ HUMAN	IAGTAVVGVLVLLVIVVAVLCLRQNSNGREAEYSDKHGQYLIGHGTKVYIDPFTYEDPN	
MACACA	EAVREFAKEIDVSYVKIEEVIGAGEFGEVCRGRLKAPGKKESCVAIKTLKGGYTERQRRE	660
_ HUMAN	EAVREFAKEIDVSYVKIEEVIGAGEFGEVCRGRLKAPGKKESCVAIKTLKGGYTERQRRE	
MACACA	FLSEASIMQFEHPPNIIIRLEGVVTNSMPVMILTEFMENGALDSFLRLNDGQFTVIQLVGM	720
_ HUMAN	FLSEASIMQFEHPPNIIIRLEGVVTNSMPVMILTEFMENGALDSFLRLNDGQFTVIQLVGM	
MACACA	LRGIASGMRYLAEMSYVHRDLAARNILVNSNLVCKVSDFGLSRFLEENSSDPTYTSSLGG	780
_ HUMAN	LRGIASGMRYLAEMSYVHRDLAARNILVNSNLVCKVSDFGLSRFLEENSSDPTYTSSLGG	
MACACA	KIPIRWTAPEAIAFRKFTSASDAWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLP	840
_ HUMAN	KIPIRWTAPEAIAFRKFTSASDAWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLP	
MACACA	PPPDCPTSLHQLMDCWQKDRNARPRFPQVVSALDKMIRNPASKIVARENGGDLLRIGV	900
_ HUMAN	PPPDCPTSLHQLMDCWQKDRNARPRFPQVVSALDKMIRNPASKIVARENGGDLLRIGV	
MACACA	TLAGHQKKILASVQHMKSQAKPGAPGGTGGPTPQY 935	
_ HUMAN	TLAGHQKKILASVQHMKSQAKPGTPGGTGGPAPQY 935	


Supplementary figure 1

Homology of the extracellular domain of human and cynomolgus EPHB4. Extracellular portion of EPHB4 amino acid sequence was highlighted in green (cynomolgus macaque; A0A2K5V953) and red (Homo Sapiens; P54760). Homology of the extracellular portion of human and cynomolgus EPHB4 was >99%.

Supplementary figure 2

Corresponding Author; Shigeki Yagyu

No Tx group (Male)




Supplementary figure 2

Histological image of heart in PBMC group. The infiltration of mononuclear cells was detected.

Supplementary figure 3

Corresponding Author; Shigeki Yagyu




Supplementary figure 3

Transposon plasmids. ECD; Extra cellular domain, ITR; Inverted Tandem Repeat, puroR; puromycin resistant gene, GFP; Green fluorescent protein gene.

Supplementary figure 4

Corresponding Author; Shigeki Yagyu



Supplementary figure 4

PB-EPHB4-CAR-T cell manufacturing scheme. Detailed manufacturing procedure was described in Materials and Methods.

Supplementary Table 1

Corresponding Author; Shigeki Yagyu

Hematology

Parameters (Unit)	n	Min	Max
HGB (g/dL)	525	10.8	15.9
HCT (%)	525	35.1	51.1
Retic ($10^9/L$)	525	11.9	115.4
WBC ($10^3/\mu L$)	524	3.48	22.08
Neut ($10^3/\mu L$)	518	0.47	11.27
Mono ($10^3/\mu L$)	522	0.14	1.11
Lymph ($10^3/\mu L$)	521	2.24	15.26
PLT ($10^3/\mu L$)	525	157	595

Biochemistry

Parameters (Unit)	n	Min	Max
AST (U/L)	901	13	81
ALT (U/L)	902	8	122
LDH (U/L)	780	141	581
CK (U/L)	838	58	1316
CRP (mg/dL)	93	0.01	0.64
BIL (mg/dL)	905	0.03	0.31
TP (g/dL)	505	6.30	8.82
ALB (g/dL)	502	3.31	4.95
UN (mg/dL)	913	10.1	32.3
CRE (mg/dL)	911	0.47	1.01
Na (mEq/L)	913	143.4	166.9
K (mEq/L)	914	3.04	6.19

Supplementary Table 1

In-house data of blood examination. Two to four-years-old healthy cynomolgus macaques housed in Ina Research Inc. from 2016 to 2019 were subjected to a blood examination to obtain the reference values. The minimum and maximum values of each parameter were determined.

Supplementary Table 2

Corresponding Author; Shigeki Yagyu

Name	clone	Product#	Company
Goat anti Ephrin B2	polyclonal	AF496	R&D SYSTEMS
PE anti-goat IgG Fc	polyclonal	F0107	R&D SYSTEMS
APC anti CD3	UCHT1	300412	Biolegend
APC anti-CD8a	HIT8a	300912	Biolegend
FITC anti-CD4	OKT4	317408	Biolegend
FITC anti-CD45RA	HI100	304106	Biolegend
APC anti-CCR7	G043H7	353214	Biolegend
Recombinant human Ephrin B2-Fc chimera protein	-	7397-EB	R&D SYSTEMS
APC anti human IgG Fc	HP6017	409306	Biolegend

Supplementary Table 2

List of antibodies used in this study.

(Forward Primer) 5'-GACTACATGAACATGACTCCCCG-3'
(Reverse Primer) 5'-GTCCAAAACATCGTACTCCTCT-3'
(probe) 5' FAM-ACCCGCAAGCATTACCAGCCCT-TAMRA 3'

Supplementary Table 3

Primer and Probe set for the detection of EPHB4-CAR transgene.